News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Robert H. Getzenberg

Articles by Robert H. Getzenberg

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

ByAdam M. Brufsky, MD, PhD,Hannah M. Linden, MD,Hope S. Rugo, MD,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Erica L. Mayer, MD, MPH

April 18th 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

ByElgene Lim, MBBS, FRACP, PhD,Adam M. Brufsky, MD, PhD,Hope S. Rugo, MD,Charles L. Vogel, MD, FACP,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Hannah M. Linden, MD

April 18th 2022

Latest Updated Articles

Trending on CancerNetwork

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

© 2025 MJH Life Sciences^®

All rights reserved.